The Starr-Edwards model 6000 mitral valve was associated with 20% operative and 42% late mortality over 15 years, though 17 of 25 survivors had improved NYHA functional class.
Cohort (n=110)
What are the long-term outcomes of patients who underwent isolated mitral valve replacement with the Starr-Edwards model 6000 valve?
Despite a high historical rate of thromboembolism and significant mortality, elective replacement of the Starr-Edwards model 6000 mitral valve is not recommended routinely.
The Starr-Edwards model 6000 mitral valve was the first successful mitral prosthesis. A fifteen year follow-up of 110 patients undergoing isolated mitral valve replacement with this prosthesis from 1960 to 1966 is presented. There were 22 (20%) operative and 37 (42%) late deaths at a mean of 8.6 years postoperatively. Preoperative variables leading to late death and thromboembolism are analyzed. Seventeen of 25 operative survivors had improvement in their NYHA Functional Class status and eight other remained unchanged an average of 13.1 years after surgery. There are 5000 patients world-wide currently relying on this prosthesis. Despite a high rate of thromboembolism in the past, elective replacement is not recommended except in selected patients.
Macmanus et al. (Sat,) conducted a cohort in Mitral valve disease requiring replacement (n=110). Starr-Edwards model 6000 mitral valve was evaluated on Late deaths. The Starr-Edwards model 6000 mitral valve was associated with 20% operative and 42% late mortality over 15 years, though 17 of 25 survivors had improved NYHA functional class.